MX2023001679A - Inmunoconjugados de pirazolazepina y usos de estos. - Google Patents
Inmunoconjugados de pirazolazepina y usos de estos.Info
- Publication number
- MX2023001679A MX2023001679A MX2023001679A MX2023001679A MX2023001679A MX 2023001679 A MX2023001679 A MX 2023001679A MX 2023001679 A MX2023001679 A MX 2023001679A MX 2023001679 A MX2023001679 A MX 2023001679A MX 2023001679 A MX2023001679 A MX 2023001679A
- Authority
- MX
- Mexico
- Prior art keywords
- immunoconjugates
- pyrazoloazepine
- provides
- intermediate compositions
- conjugation
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title abstract 4
- HMIITAWYCKLAAP-UHFFFAOYSA-N pyrazolo[4,3-b]azepine Chemical compound C1=CC=CN=C2C=NN=C21 HMIITAWYCKLAAP-UHFFFAOYSA-N 0.000 title abstract 3
- 125000005647 linker group Chemical group 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6853—Carcino-embryonic antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
La invención proporciona inmunoconjugados de Fórmula I que comprenden un anticuerpo unido por conjugación a uno o más derivados de pirazoloazepina. La invención también proporciona composiciones intermedias de derivados de pirazoloazepina que comprenden un grupo funcional reactivo. Tales composiciones intermedias son sustratos adecuados para la formación de los inmunoconjugados a través de un enlazador o de un resto enlazador. La invención proporciona además métodos para tratar cáncer con los inmunoconjugados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063065219P | 2020-08-13 | 2020-08-13 | |
PCT/US2021/045752 WO2022036101A1 (en) | 2020-08-13 | 2021-08-12 | Pyrazoloazepine immunoconjugates, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023001679A true MX2023001679A (es) | 2023-02-22 |
Family
ID=77627548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023001679A MX2023001679A (es) | 2020-08-13 | 2021-08-12 | Inmunoconjugados de pirazolazepina y usos de estos. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230263903A1 (es) |
EP (1) | EP4196168A1 (es) |
JP (1) | JP2023537940A (es) |
KR (1) | KR20230051189A (es) |
CN (1) | CN116234586A (es) |
AU (1) | AU2021326516A1 (es) |
CA (1) | CA3186059A1 (es) |
IL (1) | IL300316A (es) |
MX (1) | MX2023001679A (es) |
WO (1) | WO2022036101A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023076599A1 (en) * | 2021-10-29 | 2023-05-04 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
NZ507557A (en) | 1998-05-06 | 2003-10-31 | Genentech Inc | Protein purification by ion exchange chromatography |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
EP2264072A1 (en) | 2000-04-13 | 2010-12-22 | The Rockefeller University | Enhancement of antibody-mediated cytotoxicity. |
ES2871905T3 (es) | 2002-03-01 | 2021-11-02 | Immunomedics Inc | Inmunoconjugado que comprende anticuerpos de RS7 humanizados |
US7232888B2 (en) | 2002-07-01 | 2007-06-19 | Massachusetts Institute Of Technology | Antibodies against tumor surface antigens |
WO2005086875A2 (en) | 2004-03-11 | 2005-09-22 | City Of Hope | A humanized anti-cea t84.66 antibody and uses thereof |
DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
WO2006073921A2 (en) | 2004-12-30 | 2006-07-13 | The Rockefeller University | Compositions and methods for enhanced dendritic cell maturation and function |
US20080286819A1 (en) | 2005-11-07 | 2008-11-20 | Ravetch Jeffrey V | Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof |
PT1976880T (pt) | 2005-12-21 | 2016-09-28 | Amgen Res (Munich) Gmbh | Composições farmacêuticas com resistência a cea solúvel |
US7420041B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
US20080131428A1 (en) | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
EP2144628B1 (en) | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
MY188455A (en) | 2007-10-19 | 2021-12-09 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
HUE062339T2 (hu) | 2009-02-13 | 2023-10-28 | Immunomedics Inc | Sejten belül hasítható kötést tartalmazó immunkonjugátumok |
EP2506881B1 (en) | 2009-12-02 | 2024-03-06 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
US8709418B2 (en) | 2010-02-04 | 2014-04-29 | Toray Industries, Inc. | Pharmaceutical composition for treating CAPRIN-1 expressing cancer |
KR101624381B1 (ko) | 2010-05-17 | 2016-05-25 | 가부시키가이샤 리부텍쿠 | in vivo 에서 항종양 활성을 갖는 항인간 TROP-2 항체 |
EP2594589A1 (en) | 2010-06-10 | 2013-05-22 | Sapporo Medical University | ANTI-Trop-2 ANTIBODY |
WO2012074757A1 (en) | 2010-11-17 | 2012-06-07 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
KR101981342B1 (ko) | 2011-03-02 | 2019-05-22 | 로슈 글리카트 아게 | Cea 항체 |
EP2740793B1 (en) | 2011-08-04 | 2017-11-29 | Toray Industries, Inc. | Drug composition for cancer treatment and/or prevention |
WO2013018891A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
DK2740795T3 (en) | 2011-08-04 | 2017-01-16 | Toray Industries | Pharmaceutical composition for the treatment and / or prevention of cancer |
MX348581B (es) | 2011-08-04 | 2017-06-20 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. |
CN104053672A (zh) | 2011-11-11 | 2014-09-17 | 瑞纳神经科学公司 | Trop-2特异性抗体及其用途 |
US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
RU2633505C2 (ru) | 2012-02-21 | 2017-10-12 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
DK2818481T3 (da) | 2012-02-21 | 2019-10-14 | Toray Industries | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer |
KR102009238B1 (ko) | 2012-02-21 | 2019-08-09 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
PL2818483T3 (pl) | 2012-02-21 | 2018-01-31 | Toray Industries | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi |
CN104471404B (zh) | 2012-07-19 | 2017-03-01 | 东丽株式会社 | 癌的检测方法 |
WO2014014082A1 (ja) | 2012-07-19 | 2014-01-23 | 東レ株式会社 | 癌の検出方法 |
US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
DK2922875T3 (en) | 2012-11-20 | 2017-06-06 | Sanofi Sa | ANTI-CEACAM5 ANTIBODIES AND APPLICATIONS THEREOF |
WO2015020212A1 (ja) | 2013-08-09 | 2015-02-12 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
EP3088419B1 (en) | 2013-12-25 | 2018-10-10 | Daiichi Sankyo Company, Limited | Anti-trop2 antibody-drug conjugate |
HUE050596T2 (hu) | 2014-11-21 | 2020-12-28 | Bristol Myers Squibb Co | Antitestek CD73 ellen és azok felhasználásai |
EP3286224A4 (en) | 2015-04-22 | 2018-11-14 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
US20170158772A1 (en) | 2015-12-07 | 2017-06-08 | Opi Vi - Ip Holdco Llc | Compositions of antibody construct - agonist conjugates and methods of use thereof |
WO2017196598A1 (en) | 2016-05-10 | 2017-11-16 | Bristol-Myers Squibb Company | Antibody-drug conjugates of tubulysin analogs with enhanced stability |
KR20230149857A (ko) * | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
CN109890417A (zh) | 2016-10-28 | 2019-06-14 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
KR20190095329A (ko) * | 2016-12-13 | 2019-08-14 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | 항체-애쥬번트 접합체 |
WO2018140831A2 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
PT3595668T (pt) * | 2017-03-15 | 2021-10-21 | Silverback Therapeutics Inc | Compostos de benzazepina, conjugados, e suas utilizações |
JP2021506827A (ja) * | 2017-12-15 | 2021-02-22 | シルバーバック セラピューティックス インコーポレイテッド | 肝炎の治療用の抗体コンストラクト−薬物コンジュゲート |
CN112153988A (zh) * | 2018-05-17 | 2020-12-29 | 博尔特生物治疗药物有限公司 | 免疫缀合物 |
US20220089768A1 (en) | 2019-01-04 | 2022-03-24 | Trio Pharmaceuticals, Inc. | Multi-specific protein molecules and uses thereof |
KR20220034784A (ko) * | 2019-06-13 | 2022-03-18 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | 아미노벤즈아제핀 화합물, 면역접합체, 및 이의 용도 |
WO2020252254A1 (en) * | 2019-06-13 | 2020-12-17 | Bolt Biotherapeutics, Inc. | Macromolecule-supported aminobenzazepine compounds |
MX2022004875A (es) * | 2019-10-25 | 2022-06-17 | Bolt Biotherapeutics Inc | Inmunoconjugados de tienoazepina, inmunoconjugados y usos de estos. |
JP2022554094A (ja) * | 2019-10-25 | 2022-12-28 | ボルト バイオセラピューティクス、インコーポレーテッド | 高分子支持チエノアゼピン化合物、及びそれらの使用 |
EP4093772A1 (en) | 2020-01-21 | 2022-11-30 | Bolt Biotherapeutics, Inc. | Anti-pd-l1 antibodies |
EP4093510A1 (en) | 2020-01-21 | 2022-11-30 | Bolt Biotherapeutics, Inc. | Anti-pd-l1 antibodies |
-
2021
- 2021-08-12 EP EP21765793.1A patent/EP4196168A1/en active Pending
- 2021-08-12 MX MX2023001679A patent/MX2023001679A/es unknown
- 2021-08-12 CN CN202180056589.5A patent/CN116234586A/zh active Pending
- 2021-08-12 WO PCT/US2021/045752 patent/WO2022036101A1/en unknown
- 2021-08-12 JP JP2023509443A patent/JP2023537940A/ja active Pending
- 2021-08-12 AU AU2021326516A patent/AU2021326516A1/en active Pending
- 2021-08-12 KR KR1020237004880A patent/KR20230051189A/ko unknown
- 2021-08-12 IL IL300316A patent/IL300316A/en unknown
- 2021-08-12 CA CA3186059A patent/CA3186059A1/en active Pending
- 2021-08-12 US US18/017,541 patent/US20230263903A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022036101A1 (en) | 2022-02-17 |
US20230263903A1 (en) | 2023-08-24 |
CN116234586A (zh) | 2023-06-06 |
CA3186059A1 (en) | 2022-02-17 |
AU2021326516A1 (en) | 2023-04-13 |
KR20230051189A (ko) | 2023-04-17 |
EP4196168A1 (en) | 2023-06-21 |
JP2023537940A (ja) | 2023-09-06 |
IL300316A (en) | 2023-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021015221A (es) | Compuestos de aminobenzazepina, inmunoconjugados y usos de estos. | |
MX2022003740A (es) | Inmunoconjugados de aminobenzazepina unidos a amida y usos de estos. | |
MX2022004875A (es) | Inmunoconjugados de tienoazepina, inmunoconjugados y usos de estos. | |
MX2019008276A (es) | Conjugados de polimero multibrazo de compuestos agonistas de tlr y metodos de tratamiento inmunoterapeutico relacionados. | |
MY197127A (en) | Pyrrolobenzodiazepine conjugates | |
MX2022010515A (es) | Conjugacion mediada por transglutaminasa. | |
CR20210541A (es) | Compuestos y conjugados de estos | |
CY1113812T1 (el) | Ετεροκυκλικη ενωση και φαρμακευτικη συνθεση αυτης | |
EA201070163A1 (ru) | Цитотоксические средства, включающие новые производные томаймицина, и их терапевтическое применение | |
NO20081974L (no) | Antistoff-drug-konjugater og fremgangsmater for anvendelse av disse | |
JP2018509908A5 (es) | ||
MX2013015422A (es) | Derivados de maitansinoides novedosos con enlazador de peptido y conjugados de estos. | |
MX2020001472A (es) | Nuevo metodo para sintetizar amanitinas. | |
MX2023001679A (es) | Inmunoconjugados de pirazolazepina y usos de estos. | |
MX2023001648A (es) | Conjugado de anticuerpo y farmaco. | |
WO2022125891A3 (en) | Anti-cea immunoconjugates, and uses thereof | |
MX2022008605A (es) | Quelatos macrociclicos y sus usos. | |
MX2022012105A (es) | Composiciones de arn que se dirigen a claudina-18.2. | |
PH12021550930A1 (en) | Drug Antibody Conjugates | |
PE20230467A1 (es) | Conjugados de anticuerpo y farmaco de eribulina anti-mesotelina y metodos de uso | |
MX2020003089A (es) | Analogos de tailanstatina. | |
WO2011068894A3 (en) | Novel curcumin-antibody conjugates as anti-cancer agents | |
BR112023011315A2 (pt) | Imunoconjugado, composto, composição farmacêutica, método para tratamento de câncer e para preparar um imunoconjugado e uso de um imunoconjugado | |
SG11201903084UA (en) | Cysteine modified antibody-drug conjugate and preparation method thereof | |
WO2023031623A3 (en) | Synthesis of bicycle toxin conjugates, and intermediates thereof |